This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kytölä, S. Articles by Kjellman, M. Search for Related Content PubMed PubMed Citation Articles by Kytölä, S. Articles by Kjellman, M.

(American Journal of Pathology. 2001;158:1803-1808.)
© 2001 American Society for Investigative Pathology

Regular Articles

Comparative Genomic Hybridization Identifies Loss of 18q22-qter as an Early and Specific Event in Tumorigenesis of Midgut Carcinoids

Soili Kytölä^*, Anders Höög, Brita Nord^*, Björn Cedermark, Tony Frisk^*, Catharina Larsson^* and Magnus Kjellman^*

From the Departments of Molecular Medicine,^*
Oncology and Pathology,
and Surgery,
Karolinska Hospital, Stockholm, Sweden; and the Laboratory of Cancer Genetics,
Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland

Carcinoid tumors are rare neuroendocrine tumors occurring in the lung or in the digestive tract where they are further subclassified as foregut, midgut, or hindgut carcinoids. To gain a better understanding of the genetic basis of the different types of carcinoid tumors, we have characterized numerical imbalances in a series of midgut carcinoids, and compared the results to previous findings in carcinoids from the lung. Numerical imbalances were revealed in 16 of the 18 tumors, and the most commonly detected aberrations were losses of 18q22-qter (67%), 11q22-q23 (33%), and 16q21-qter (22%), and gain of 4p14-qter (22%). The total number of alterations found in the metastases was significantly higher than in the primary tumors, indicating the accumulation of acquired genetic changes in the tumor progression. Losses of 18q and 11q were present both in primary tumors and metastases, whereas loss of 16q and gain of 4 were only detected in metastases. Furthermore, the pattern of comparative genomic hybridization alterations varied depending on the total number of detected alterations. Taken together, the findings would suggest a progression of numerical imbalances, in which loss of 18q and 11q represent early events, and loss of 16q and gain of 4p are late events in the tumor progression of midgut carcinoids. When compared to previously published comparative genomic hybridization abnormalities in lung carcinoids, loss of 11q was found to occur in both tumor types, whereas loss of 18q and 16q and gain of 4 were not revealed in lung carcinoids. The results indicate that inactivation of a putative tumor suppressor gene in 18q22-qter represents a frequent and early event that is specific for the development of midgut carcinoids.

This article has been cited by other articles:

				E.-M. Duerr, Y. Mizukami, A. Ng, R. J Xavier, H. Kikuchi, V. Deshpande, A. L Warshaw, J. Glickman, M. H Kulke, and D. C Chung Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis Endocr. Relat. Cancer, March 1, 2008; 15(1): 243 - 256. [Abstract] [Full Text] [PDF]

				G. Van Buren II, A. Rashid, A. D. Yang, E. K. Abdalla, M. J. Gray, W. Liu, R. Somcio, F. Fan, E. R. Camp, J. C. Yao, et al. The Development and Characterization of a Human Midgut Carcinoid Cell Line Clin. Cancer Res., August 15, 2007; 13(16): 4704 - 4712. [Abstract] [Full Text] [PDF]

				J. C. Yao, J. X. Zhang, A. Rashid, S.-C. J. Yeung, J. Szklaruk, K. Hess, K. Xie, L. Ellis, J. L. Abbruzzese, and J. A. Ajani Clinical and In vitro Studies of Imatinib in Advanced Carcinoid Tumors Clin. Cancer Res., January 1, 2007; 13(1): 234 - 240. [Abstract] [Full Text] [PDF]

				T. M. Katona, T. D. Jones, M. Wang, F. W. Abdul-Karim, O. W. Cummings, and L. Cheng Molecular Evidence for Independent Origin of Multifocal Neuroendocrine Tumors of the Enteropancreatic Axis. Cancer Res., May 1, 2006; 66(9): 4936 - 4942. [Abstract] [Full Text] [PDF]

				G. KLOPPEL, A. PERREN, and P. U. HEITZ The Gastroenteropancreatic Neuroendocrine Cell System and Its Tumors: The WHO Classification Ann. N.Y. Acad. Sci., April 1, 2004; 1014(1): 13 - 27. [Abstract] [Full Text] [PDF]

				N Scott, E Millward, E J Cartwright, S R Preston, and P L Coletta Gastrin releasing peptide and gastrin releasing peptide receptor expression in gastrointestinal carcinoid tumours J. Clin. Pathol., February 1, 2004; 57(2): 189 - 192. [Abstract] [Full Text] [PDF]

				D. Furlan, R. Cerutti, S. Uccella, S. La Rosa, E. Rigoli, A. Genasetti, and C. Capella Different Molecular Profiles Characterize Well-Differentiated Endocrine Tumors and Poorly Differentiated Endocrine Carcinomas of the Gastroenteropancreatic Tract Clin. Cancer Res., February 1, 2004; 10(3): 947 - 957. [Abstract] [Full Text] [PDF]

				S. U. Goebel, M. Iwamoto, M. Raffeld, F. Gibril, W. Hou, J. Serrano, and R. T. Jensen HER-2/neu Expression and Gene Amplification in Gastrinomas: Correlations with Tumor Biology, Growth, and Aggressiveness Cancer Res., July 1, 2002; 62(13): 3702 - 3710. [Abstract] [Full Text] [PDF]